ClinicalTrials.gg
RecruitingNCT07225270RAINFOL-04Updated Nov 16, 2026

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

A Phase 3 interventional study of Rina-S and Bevacizumab in Ovarian Cancer, Platinum-sensitive Ovarian Cancer and PSOC, sponsored by Genmab. Recruiting at 69 sites in 16 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Genmab · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 16, 2026First sites in 13 new countriesEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Planned enrollment
100th of 1,498
544 · median 47
Started
2026
with 64 others
Phase 3
103 of 1,779
18 open now
Primary completion
2028-10
later than 341 of 452 live
Registered
1,721st of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 100th largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 65 that started in 2026, is one of 103 in phase 3, reaches primary completion later than 341 of the 452 other live ones, and was the 1,721st registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase 3 study will be conducted in different countries around the world with up to about 544 participants.

The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer.

Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms.

The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.

Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.

Read the detailed description

This is a randomized, open-label, Phase 3 study of Rina-S + standard of care (SOC) versus SOC as maintenance treatment after second-line (2L) platinum-based doublet chemotherapy in participants with recurrent PSOC.

03

Conditions studied

  • Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • PSOC

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have or cytologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
  • Must have PSOC defined as progressive disease > 6 months (ie, 183 days) from the last dose of primary ( [1L]) platinum therapy.
  • Participants with known breast cancer (BRCA)-mutated (somatic or germline) or homologous recombination deficiency (HRD)-positive ovarian cancer who achieved complete response (CR)/no clinical evidence of disease (NED) or partial response (PR) following 1L platinum-based chemotherapy regimen must have previously received PARPi maintenance therapy as part of their 1L treatment.
  • Must have completed platinum-based chemotherapy in the 2L treatment for recurrent PSOC.
  • Must be randomized no later than 8 weeks from the last dose of the 2L platinum-based therapy.
  • Participants must have achieved a CR/NED, PR; or SD permitted only if bevacizumab (≥3 cycles) was given in 2L in combination with platinum-based chemotherapy, as assessed by the investigator, following completion of 2L platinum-based chemotherapy.

Key Exclusion Criteria:

  • Participants with clear cell, mucinous, or sarcomatous histology, mixed tumors containing any of the above histologies, or low-grade/borderline ovarian tumors
  • More than 2 prior lines of systemic therapy.
  • Progression while on or following 2L platinum-based regimen prior to randomization.
  • Participants who receive an intervening systemic anticancer treatment (excluding bevacizumab) after the last dose of 2L platinum-based chemotherapy and prior to randomization.

Note: Other protocol-defined Inclusion and Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
544 participants (estimated)

Study arms

  • Experimental
    Rina-S + SOC

    Participants will receive Rina-S and SOC consisting of either bevacizumab maintenance or no maintenance treatment (observation).

    Drug: Rina-S · Drug: Bevacizumab

  • Active comparator
    SOC

    Participants will receive SOC consisting of either bevacizumab maintenance or no maintenance treatment (observation).

    Drug: Bevacizumab

Interventions

  • DrugRina-S

    Intravenous (IV) infusion

    Also known as: Rinatabart sesutecan, GEN1184, PRO1184

  • IV infusion

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR)

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Overall Survival

    Time frame: Up to approximately 4 years

  2. PFS, per RECIST 1.1, as Determined by Investigator Assessment

    Time frame: Up to approximately 3 years

  3. Second Determination of PFS (PFS2)

    Time frame: Up to approximately 4 years

  4. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 4 years

  5. Overall Change from Baseline in Global Health Status (GHS)/Quality of Life (QoL) Score Using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Questionnaire

    Time frame: Up to approximately 4 years

  6. Time to Deterioration (TTD) in the GHS/QoL Score Using the QLQ-C30

    Time frame: Up to approximately 4 years

07

Study locations

69 of 69 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 30 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2025
First posted
Nov 6, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Oct 2028
CompletionEst.
May 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
47 sites added — first sites in Finland, France, Norway, Poland, Spain and 8 more
All 13 countries

Finland, France, Norway, Poland, Spain, Australia, Austria, Denmark, Germany, Italy, Puerto Rico, South Korea, United Kingdom

Show 47 added (11 United States, 6 France, 5 South Korea, 4 Belgium, 4 Finland, 3 Poland, 3 Spain, 2 Norway, 2 Denmark, 2 Germany, 1 Australia, 1 Austria, 1 Italy, 1 Puerto Rico, 1 United Kingdom)
  • Missouri Cancer Associates · Columbia, United States
  • Methodist Estabrook Cancer Center · Omaha, United States
  • Novant Health Presbyterian Medical Center · Charlotte, United States
  • Alliance Cancer Specialists - Abington Hematology Oncology Associates - Horsham · Horsham, United States
  • AZ Delta - Uw Ziekenhuis · Roeselare, Belgium
  • AZ Nikolaas · Sint-Niklaas, Belgium
  • Kuopion Yliopistollinen Sairaala · Kuopio, Finland
  • Hôpital Privé du Confluent · Nantes, France
  • Hôpital René Huguenin · Saint-Cloud, France
  • Haukeland University Hospital · Bergen, Norway
  • Białostockie Centrum Onkologii im. M. Skłodowskiej-Curie w Białymstoku · Bialystok, Poland
  • Complejo Hospitalario Universitario A Coruña · A Coruña, Spain
  • University Of California Davis Medical Center · Sacramento, United States
  • Hartford Hospital · Hartford, United States
  • Florida Cancer Specialists & Research Institute - New Port Richey · New Port Richey, United States
  • Maine Medical Center Cancer Institute Breast Care Center · Scarborough, United States
  • Penn State Health Milton South Hershey Medical Center · Hershey, United States
  • Texas Oncology - Northeast Texas · San Antonio, United States
  • Virginia Cancer Specialists - Fairfax · Fairfax, United States
  • Prince of Wales Hospital · Randwick, Australia
  • Medizinische Universitaet Innsbruck · Innsbruck, Austria
  • Les Cliniques du Sud Luxembourg, Clinique Saint-Joseph · Arlon, Belgium
  • AZ Maria Middelares · Ghent, Belgium
  • Aalborg University Hospital · Aalborg, Denmark
  • Roskilde Sygehus · Roskilde, Denmark
  • Oulu University Hospital · Oulu, Finland
  • Tampereen yliopistollinen sairaala - Tampere · Tampere, Finland
  • Tyks Majakkasairaala · Turku, Finland
  • Centre Hospitalier de Mont-de-Marsan · Mont-de-Marsan, France
  • Centre Antoine-Lacassagne - Site Est · Nice, France
  • …and 17 more on the registry record
across 2 updates, Oct 6, 2026 – Nov 16, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedParticipants must have achieved a CR/NED, PR; or SD permitted only if bevacizumab (≥3 cycles) was given in 2L in combination with platinum-based chemotherapy, as assessed by the investigator, following completion of 2L platinum-based chemotherapy.
Nov 16, 2026
Show all 2 updates
  1. Nov 16, 2026
    35 sites added — first sites in Australia, Austria, Denmark, Germany, Italy and 3 more
    All 8 countries

    Australia, Austria, Denmark, Germany, Italy, Puerto Rico, South Korea, United Kingdom

    Show 35 added (7 United States, 5 South Korea, 4 France, 3 Finland, 2 Belgium, 2 Denmark, 2 Germany, 2 Poland, 2 Spain, 1 Australia, 1 Austria, 1 Italy, 1 Norway, 1 Puerto Rico, 1 United Kingdom)
    • University Of California Davis Medical Center · Sacramento, United States
    • Hartford Hospital · Hartford, United States
    • Florida Cancer Specialists & Research Institute - New Port Richey · New Port Richey, United States
    • Maine Medical Center Cancer Institute Breast Care Center · Scarborough, United States
    • Penn State Health Milton South Hershey Medical Center · Hershey, United States
    • Texas Oncology - Northeast Texas · San Antonio, United States
    • Virginia Cancer Specialists - Fairfax · Fairfax, United States
    • Prince of Wales Hospital · Randwick, Australia
    • Medizinische Universitaet Innsbruck · Innsbruck, Austria
    • Les Cliniques du Sud Luxembourg, Clinique Saint-Joseph · Arlon, Belgium
    • AZ Maria Middelares · Ghent, Belgium
    • Aalborg University Hospital · Aalborg, Denmark
    • Roskilde Sygehus · Roskilde, Denmark
    • Oulu University Hospital · Oulu, Finland
    • Tampereen yliopistollinen sairaala - Tampere · Tampere, Finland
    • Tyks Majakkasairaala · Turku, Finland
    • Centre Hospitalier de Mont-de-Marsan · Mont-de-Marsan, France
    • Centre Antoine-Lacassagne - Site Est · Nice, France
    • Groupe Hospitalier Paris Saint-Joseph · Paris, France
    • Centre Hospitalier Universitaire de Poitiers · Poitiers, France
    • Klinikum Gütersloh · Gütersloh, Germany
    • SLK-Kliniken Heilbronn · Heilbronn, Germany
    • Ospedale Humanitas San Pio X · Milan, Italy
    • Sorlandet Sykehus Kristiansand · Kristiansand, Norway
    • Instytut Centrum Zdrowia Matki Polki · Lodz, Poland
    • Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli · Lublin, Poland
    • Puerto Rico Medical Research Center · San Juan, Puerto Rico
    • National Cancer Center · Gyeonggi-do, South Korea
    • Gachon University Gil Medical Center · Incheon, South Korea
    • Asan Medical Center · Seoul, South Korea
    • …and 5 more on the registry record
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedParticipants must have achieved a CR/NED, PR; or SD permitted only if bevacizumab (≥3 cycles) was given in 2L in combination with platinum-based chemotherapy, as assessed by the investigator, following completion of 2L platinum-based chemotherapy.
    + 2 other changes: identifiers and verification date
  2. Oct 6, 2026
    12 sites added — first sites in Finland, France, Norway, Poland and Spain
    Show 12 added (4 United States, 2 Belgium, 2 France, 1 Finland, 1 Norway, 1 Poland, 1 Spain)
    • Missouri Cancer Associates · Columbia, United States
    • Methodist Estabrook Cancer Center · Omaha, United States
    • Novant Health Presbyterian Medical Center · Charlotte, United States
    • Alliance Cancer Specialists - Abington Hematology Oncology Associates - Horsham · Horsham, United States
    • AZ Delta - Uw Ziekenhuis · Roeselare, Belgium
    • AZ Nikolaas · Sint-Niklaas, Belgium
    • Kuopion Yliopistollinen Sairaala · Kuopio, Finland
    • Hôpital Privé du Confluent · Nantes, France
    • Hôpital René Huguenin · Saint-Cloud, France
    • Haukeland University Hospital · Bergen, Norway
    • Białostockie Centrum Onkologii im. M. Skłodowskiej-Curie w Białymstoku · Bialystok, Poland
    • Complejo Hospitalario Universitario A Coruña · A Coruña, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225270
Lead sponsor
Genmab
Responsible party
Sponsor
First posted
Nov 6, 2025
Start date
Apr 3, 2026
Primary completion
Oct 2028 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Genmab Trial Information
Contact
clinicaltrials@genmab.com
+4570202728
Study Official
study director · Genmab

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rinatabart sesutecan

Start the discussion